// App-Quantinova.ai

e13528 : The effect of tivantinib on QTc interval in subjects with advanced solid tumors and healthy subjects.

Researchers

Presenter

  • Masaya Tachibana

Principal Investigators

  • Kyriakos P. Papadopoulos

  • Lon S. Smith

  • Monica M. Mita

  • Ronald B. Natale

  • Joel Morganroth

  • Ronald Savage

  • Roohi Gajee

  • Shuquan Chen

  • Hamim Zahir

  • Danielle Mutz

  • Alain C. Mita

Medical Centers

  • ArQule, Inc., Woburn, MA

  • Consultant, ERT (eResearchTechnology, Inc.), Philadelphia, PASamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CASouth Texas Accelerated Research Therapeutics (START) Center for Cancer Care, San Antonio, TX

  • Daiichi Sankyo, Inc., Edison, NJ

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Tivantinib

Outcome

  • Indeterminate

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01699061

Sponsors

  • ArQule, Inc.

  • Daiichi Sankyo

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved